Contract Backlog Expands to C$2.5M, FDA CPIM Completed, Nature Portfolio Study Accepted, Major Channel Partner Onboarding, and CAMH Research Award SecuredTORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today provided a business update highlighting significant progre ...

TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced alongside the Centre for Addiction and Mental Health (CAMH) in Toronto, one of the world’s leading mental-health research hospitals, that they have been named recipients of the prestigious Ontario Research Fun ...

TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced the completion of its Critical Path Innovation Meeting (CPIM) with the U.S. Food and Drug Administration (FDA). During this scientific exchange, FDA provided feedback on NetraAI—NetraMark's explainable ...

Core Insights - NetraMark Holdings Inc. has secured a new contract with a global biopharmaceutical company to provide analytics support for a pivotal Phase 3 clinical trial, highlighting the company's growing influence in the pharmaceutical sector [1][2]. Group 1: Contract and Project Details - The new engagement is part of an existing master services agreement and represents a discrete project aimed at enhancing decision support in Phase 3 trials, showcasing the increasing interest in NetraAI technology [2][4]. - NetraMark will utilize its NetraAI platform to identify and characterize patient subpopulations, including responders and non-responders, which will aid in interpreting treatment response patterns and variability within the study population [3][4]. Group 2: Technology and Methodology - NetraAI is designed to separate small datasets into explainable and unexplainable subsets, which helps avoid overfitting and enhances the accuracy of insights derived from clinical trials [5][6]. - The technology's unique focus mechanisms allow for better segmentation of diseases and classification of patient responses, thereby increasing the likelihood of clinical trial success [5][6]. Group 3: Company Position and Future Outlook - The CEO of NetraMark emphasized the growing trust from biopharmaceutical companies in the value of explainable AI for high-stakes development programs, indicating a positive trajectory for the company's future engagements [4][7]. - This contract reinforces NetraMark's position in AI-powered clinical trial optimization and suggests potential for further growth as the company becomes integrated into standard operating procedures of biopharmaceutical firms [4][7].

TORONTO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that its peer-reviewed paper, “Explainable AI-Driven Precision Clinical Trial Enrichment: Demonstration of the NetraAI Platform with a Phase II Depression Trial,” has been accepted for publication in np ...

Core Insights - NetraMark Holdings Inc. has signed four contracts with a leading global pharmaceutical company to provide advanced AI analytics for multiple late-stage clinical studies [1][4] - The proprietary NetraAI platform will be utilized to analyze clinical data from these studies, focusing on identifying patient subpopulations that influence treatment and placebo responses [2][3] Group 1: Contract Details - The contracts represent a significant expansion of the ongoing collaboration between NetraMark and the pharmaceutical company, reflecting continued confidence in NetraMark's technology [3][4] - Each study will leverage the NetraAI system, which is designed to identify high-effect-size subgroups within complex datasets, aligning with FDA expectations for explainable AI in clinical development [3][5] Group 2: Technology Overview - NetraAI is engineered to separate small datasets into explainable and unexplainable subsets, enhancing the accuracy of insights derived from clinical data [5][6] - The technology allows for the analysis of smaller datasets while accurately classifying patients based on their sensitivity to drugs and treatment efficacy [6]

Core Insights - NetraMark Holdings Inc. has signed a contract with a leading biopharmaceutical company to utilize its NetraAI platform in a Phase 3 clinical trial for a new psychiatric medicine, indicating the company's growing influence in the pharmaceutical industry [1][2]. Company Overview - NetraMark is focused on transforming clinical trials through AI-powered precision analytics, specifically targeting the pharmaceutical sector [1][6]. - The company employs a unique topology-based algorithm that allows for effective analysis of small, complex clinical datasets, enhancing the understanding of patient heterogeneity [6]. Technology and Methodology - The NetraAI platform utilizes a dynamical systems framework to analyze multi-dimensional clinical data, identifying explainable subpopulations related to treatment responses and adverse events [2][3]. - Unlike traditional AI methods, NetraAI incorporates focus mechanisms that separate datasets into explainable and unexplainable subsets, reducing the risk of overfitting and improving the accuracy of insights [5]. Industry Impact - The engagement with the biopharmaceutical company reflects a growing recognition of the value of explainable AI in improving clinical trial success rates [3][4]. - NetraMark's technology aims to provide actionable insights that can inform regulatory and market access strategies, thereby supporting drug development success [2][4].

Core Insights - NetraMark Holdings Inc. is leveraging its AI technology, NetraAI, to enhance clinical trials in the pharmaceutical industry, particularly for major depressive disorder (MDD) [1][10] Group 1: Presentation Highlights - At the ISCTM Autumn conference and ECNP Congress, NetraMark showcased two significant applications of its technology, focusing on ketamine and escitalopram trials [1][5] - The first presentation demonstrated how NetraAI identified distinct patient responder subgroups in ketamine trials, revealing that ketamine responders had unique baseline characteristics compared to placebo responders [2][3] - The second presentation introduced a novel algorithm that improved predictive accuracy in heterogeneous MDD trials, specifically for escitalopram response, by identifying a compact feature set related to anhedonia and mood [5][6] Group 2: Key Findings - In the ketamine trial, responder subgroups diverged significantly from placebo responders by the second infusion, indicating that ketamine's efficacy is not merely due to functional unblinding [4][8] - NetraAI's analysis in the CAN-BIND trial reduced clinical variables from 718 to 8 key variables, enhancing prediction accuracy and identifying a subgroup of highly predictive responders [9][7] - The technology revealed a genetic signature linked to neuroplasticity, allowing for a 91% accuracy in predicting treatment success when retrained on specific features [17] Group 3: Implications for Clinical Trials - NetraAI's capabilities can help overcome traditional barriers in CNS drug development by improving patient stratification, reducing placebo-related noise, and enhancing predictive modeling [10][12] - The advancements in distinguishing true pharmacologic effects from placebo responses represent a significant step forward in the design and interpretation of psychiatric and CNS trials [11][12] - As precision medicine becomes increasingly important, NetraMark's innovations provide a robust toolkit for pharmaceutical companies to uncover meaningful patient subgroups and accelerate drug development timelines [12][14]

Core Insights - NetraMark Holdings Inc. has announced a collaboration focused on glioblastoma (GBM) research, utilizing proprietary know-how and access to clinical and biomarker datasets from a leading U.S. academic medical center [1][5] Group 1: Collaboration and Objectives - The collaboration aims to apply NetraAI, the company's explainable AI platform, to identify patient subgroups for developing a therapeutic decision support tool for future GBM trials [2] - Specific objectives include generating insights from longitudinal cerebrospinal fluid (CSF) proteomic datasets and creating NetraPersonas to optimize trial enrichment strategies [4][5] Group 2: Glioblastoma Challenges - Glioblastoma is characterized by a median survival of just 15 months, with less than 7% of patients surviving beyond five years, and clinical trials have a failure rate exceeding 90% due to heterogeneous patient populations and limited predictive biomarkers [3] Group 3: Data Utilization and Analysis - The academic partner will provide expanded longitudinal glioblastoma proteomic datasets generated on the SomaLogic platform, which will be analyzed to identify molecular markers and understand treatment impacts [5][7] - NetraAI's unique focus mechanisms allow for the separation of small datasets into explainable and unexplainable subsets, enhancing the potential for accurate insights and reducing the risk of overfitting [6][8]

Core Viewpoint - NetraMark Holdings Inc. has signed a contract with Asklepion Pharmaceuticals to utilize its NetraAI platform for analyzing data from a pivotal Phase III pediatric clinical trial focused on intravenous L-citrulline for preventing acute lung injury in children undergoing cardiopulmonary bypass surgery for congenital heart defects [1][2]. Group 1: Company Overview - NetraMark is a leader in developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions specifically for the pharmaceutical industry [5]. - The company's technology employs a novel topology-based algorithm that can parse patient data into related subsets, allowing for accurate disease segmentation and patient classification regarding drug sensitivity and treatment efficacy [5]. Group 2: Partnership Details - The agreement with Asklepion aims to enhance the ability to demonstrate the benefits of L-citrulline in specific patient subgroups through the application of NetraAI's advanced AI technology [2][3]. - NetraMark's analysis will focus on identifying responder personas, which are subpopulations of patients most likely to benefit from the treatment, thereby informing future study designs for L-citrulline development [4]. Group 3: Strategic Importance - Asklepion's engagement with NetraMark reflects a commitment to innovation in trial design, aiming to uncover meaningful insights that can optimize patient selection and improve study outcomes [4]. - The integration of NetraAI's explainable AI analytics into Asklepion's late-phase study is expected to sharpen the understanding of L-citrulline and accelerate the development of safer, more effective treatments for children [4].